Galmed Competitors
| GLMD Stock | USD 0.62 -0.0048 -0.77% |
Correlation: Galmed Pharmaceuticals vs NKGen Biotech Details
Very good diversification
The correlation between GLMD and NKGN is -0.45, which Macroaxis classifies as Very good diversification for the selected horizon. Used correctly, the chart helps investors judge whether adding the second position genuinely diversifies the first.
Moving together with Galmed Stock
Moving against Galmed Stock
While mean reversion in Galmed Pharmaceuticals' is a statistically observable tendency, it operates on uncertain timelines. Positions sized too aggressively against the trend can suffer sustained losses before reversion occurs.
Galmed Pharmaceuticals Competition Correlation Matrix
Correlation analysis between Galmed Pharmaceuticals and its competitors helps investors understand whether diversification is real or only superficial inside the same peer group. This matrix is most informative when investors want to know whether adding another peer would improve diversification, increase crowding, or leave total risk largely unchanged.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Galmed Stock performing well and Galmed Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Galmed Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| BIVI | 3.38 | -0.07 | 0.00 | -0.04 | 0.00 | 8.66 | 23.28 | |||
| TOVX | 4.89 | -0.07 | 0.00 | -0.03 | 0.00 | 11.11 | 38.10 | |||
| MLEC | 11.97 | 2.32 | 0.19 | 0.65 | 11.15 | 47.61 | 152.55 | |||
| CMMB | 4.14 | -0.37 | 0.00 | -0.29 | 0.00 | 8.61 | 28.67 | |||
| INM | 4.06 | -0.34 | 0.00 | -0.23 | 0.00 | 7.48 | 27.74 | |||
| BDRX | 8.27 | -1.23 | 0.00 | -0.88 | 0.00 | 19.44 | 128.35 | |||
| VRAX | 5.84 | -0.38 | 0.00 | -0.12 | 0.00 | 10.00 | 92.80 | |||
| ELAB | 6.96 | -4.39 | 0.00 | -1.01 | 0.00 | 8.62 | 53.38 | |||
| ISPC | 5.79 | -0.61 | 0.00 | -0.19 | 0.00 | 10.00 | 41.56 | |||
| NKGN | 15.02 | 6.42 | 0.22 | -0.99 | 9.08 | 35.14 | 298.33 |
Peer Comparison: Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Galmed Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Galmed Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Compare Galmed Pharmaceuticals and related stocks such as Biovie Inc, Theriva Biologics, and Moolec Science SA Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BIVI | -70 K | -70 K | -70 K | -321.9 K | -233 K | -431.9 K | -1.3 M | -2.4 M | -2.4 M | -16.7 M | -130.2 M | -26.1 M | -50.3 M | -32.1 M | -17.5 M | -15.8 M | -16.6 M |
| TOVX | -3.9 M | -8.1 M | -17.1 M | -12.3 M | -19.8 M | -43.7 M | -27.3 M | -15.2 M | -13.4 M | -15.3 M | -10 M | -14.2 M | -19.7 M | -18.3 M | -25.7 M | -23.1 M | -21.9 M |
| MLEC | -13.8 K | -13.8 K | -13.8 K | -13.8 K | -13.8 K | -13.8 K | -13.8 K | -13.8 K | -13.8 K | -13.8 K | -13.8 K | -4.5 M | -51.8 M | -7.3 M | -111.5 M | -100.3 M | -95.3 M |
| CMMB | -3 M | -6 M | 24.2 M | -5.8 M | -6 M | -7.5 M | -4.7 M | -9.8 M | 13.3 M | 27.1 M | -6 M | -12.5 M | -27.6 M | -24.2 M | -13.9 M | -12.6 M | -11.9 M |
| INM | -4.3 M | -189.9 K | -46.7 K | -1.2 M | -3.5 M | -1.8 M | -3.4 M | -6.7 M | -10 M | -8.9 M | -12.6 M | -18.6 M | -7.9 M | -7.7 M | -8.2 M | -7.3 M | -7 M |
| BDRX | -4 M | -4 M | -4 M | -4.1 M | -8.8 M | -10.1 M | -6.2 M | -11.7 M | -10.4 M | -10.1 M | -22.2 M | -5.5 M | -7.7 M | -7.1 M | -5.7 M | -5.2 M | -5.4 M |
| VRAX | -801.1 K | -801.1 K | -801.1 K | -801.1 K | -801.1 K | -801.1 K | -801.1 K | -801.1 K | -801.1 K | -801.1 K | -651 K | -1.7 M | -5.5 M | -6.7 M | -6.1 M | -5.5 M | -5.7 M |
| ELAB | -222.9 K | -222.9 K | -222.9 K | -222.9 K | -222.9 K | -222.9 K | -222.9 K | -222.9 K | -222.9 K | -222.9 K | -222.9 K | -784.7 K | -1.8 M | -4.3 M | -6.2 M | -5.6 M | -5.3 M |
| ISPC | -5.3 M | -5.3 M | -5.3 M | -5.3 M | -5.3 M | -5.3 M | -5.3 M | -5.3 M | -5.3 M | -4.7 M | -4.7 M | -9 M | -10.2 M | -11.1 M | -12.5 M | -11.2 M | -11.8 M |
Galmed Pharmaceuticals Competitive Analysis
Examining Galmed Pharmaceuticals performance alongside its competitors is a fundamental step in evaluating any equity investment. Competitive benchmarking of Galmed Pharmaceuticals' key financial ratios reveals whether the company is a sector leader or laggard.| Better Than Average | Worse Than Peers | View Performance Chart |
Galmed Pharmaceuticals Peer Performance Charts
How to Analyze Galmed Pharmaceuticals Against Peers
Galmed Pharmaceuticals' peer analysis compares Galmed Pharmaceuticals with related companies to put valuation, quality, and risk metrics in context. This helps determine whether recent performance is company-specific or broadly sector-driven. A practical workflow includes:- Set a relevant peer group: Include direct competitors and close alternatives with comparable business exposure.
- Benchmark core financials: Compare profitability, growth, capital structure, and cash flow quality.
- Check valuation dispersion: Review whether Galmed Pharmaceuticals trades at a premium or discount versus peers and why.
- Evaluate risk profile: Compare volatility, drawdowns, and correlation to avoid false diversification assumptions.
- Document the thesis: Record where Galmed Pharmaceuticals leads or lags and what catalysts could close or widen the gap.